Related Experiment Videos
Malignant hyperthermia and the otolaryngologist.
Christopher Y Chang1, Richard L Scher
1Division of Otolaryngology-Head and Neck Surgery, Department of Surgery, Duke University Medical Center, Box 3805, Durham, NC 27710, USA. chang020@mc.duke.edu
Ear, Nose, & Throat Journal
|July 17, 2003
Summary
Malignant hyperthermia (MH) prevention has advanced, focusing on pre-operative management and anesthetic selection. Routine prophylactic drugs are no longer needed, and local anesthetics are now safe for susceptible patients.
Area of Science:
- Anesthesiology
- Pharmacology
Background:
- Malignant hyperthermia (MH) is a rare, life-threatening pharmacogenetic disorder of skeletal muscle.
- It is triggered by volatile anesthetics and succinylcholine in susceptible individuals.
Observation:
- Prevention strategies for MH have evolved, emphasizing pre-operative patient management and anesthetic agent selection.
- Local anesthetics, including lidocaine, are now considered safe for MH-susceptible patients.
- Routine preoperative prophylactic drug administration, including dantrolene, is no longer recommended.
Findings:
- Anesthetic management for MH-susceptible patients depends on the procedure's stress level.
- Low-stress procedures allow same-day discharge from ambulatory centers if triggering agents are avoided.
- High-stress procedures necessitate hospitalization for MH-susceptible patients.
Implications:
- Updated MH prevention guidelines enhance patient safety during anesthesia.
- Anesthesiologists can now utilize a broader range of anesthetic agents, including local anesthetics.
- Careful patient selection and facility preparedness are crucial for managing MH risk.